EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer

NCT02183870 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer
Adenocarcinoma
NSCLC

Interventions

DRUG: Crizotinib

Sponsor

University of Cologne

Collaborators

[object Object]
[object Object]